45 results on '"Puenpatom, Amy"'
Search Results
2. Progression of the FIB-4 index among patients with chronic HCV infection and early liver disease
3. Impact of Molnupiravir Treatment on Patient-Reported Coronavirus Disease 2019 (COVID-19) Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
4. Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy
5. Prevalence of Potential Drug-Drug Interactions With Ritonavir-Containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey
6. Potential Cyp3a4-Mediated Drug-Drug Interactions with Ritonavir-Containing Medications in U.S. Patients with Diabetes or Cardiovascular Diseases: An Analysis of Nhanes Data
7. Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection
8. Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19
9. Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study
10. Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
11. Correction to: Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study
12. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population
13. Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study
14. Correction to: Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective Study
15. Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis: A Retrospective Study
16. A Tool to Inform Hepatitis C Elimination: A Case for Hepatitis C Elimination in China
17. Evaluating the power of the causal impact method in observational studies of HCV treatment as prevention
18. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience
19. Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR
20. Efficacy and safety of elbasvir/grazoprevir in treatment‐naive Chinese adults with hepatitis C virus infection: A randomized trial
21. Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong
22. Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection
23. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population
24. Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis – A Systematic Literature Review
25. Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis
26. AB0402 MEASURING PATIENT EXPERIENCE OF SWITCHING BIOLOGIC TREATMENT – A SYSTEMATIC LITERATURE REVIEW
27. Tu1495 – Real-World Effectiveness of Elbasvir/Grazoprevir in Patients with Hepatitis C Virus Genotype 4 Infection: Results from a Veterans Affairs Population
28. 955 – Effectiveness of Elbasvir/Grazoprevir in Patients with Hepatitis C Virus Genotype 1 Inffection Who Receive Opioid Agonist Therapy: Treatment Utilization and the Impact of Concomitant Psychiatric Medications
29. Tu1504 – Effectiveness of Elbasvir/Grazoprevir in Patients with Hepatitis C Virus Genotype 1 Infection Receiving Dialysis
30. THU-170-Real-world effectiveness of elbasvir/grazoprevir in patients with hepatitis C virus genotype 4 infection: Results from a Veterans Affairs population
31. PS-182-Effectiveness of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 infection who receive opioid agonist therapy: Treatment utilization and the impact of concomitant psychiatric medications
32. THU-171-Effectiveness of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 infection receiving dialysis
33. The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection
34. FRI-248-Cost-effectiveness of elbasvir/grazoprevir (EBR/GZR) for treatment-naive (TN) patients with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infection in Russia
35. 293 - Effectiveness and Utilization of Elbasvir/Grazoprevir in HCV Genotype 1 and 4 Infection in the Veteran Affairs Healthcare System in the United States
36. Mo1401 - Impact of Acid-Reducing Agents on Effectiveness of Elbasvir/Grazoprevir in a us Veterans Affairs Population with Hepatitis C Virus Infection
37. HCV treatment initiation in persons with chronic kidney disease in the directly acting antiviral agents era: Results from ERCHIVES
38. Initial Uptake and Time to Treatment of all Oral Direct Acting Antivirals for Hepatitis C
39. Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States
40. Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens
41. Real World Experience with Elbasvir/Grazoprevir in the Veterans Affairs Healthcare System
42. Treatment Uptake and Real World Effectiveness of Sofosbuvir/Ledipasvir and Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir Among HCV-Infected Persons with Chronic Kidney Disease
43. Effectiveness and Safety of Sofosbuvir/Ledipasvir and Paritaprevir/ritonavir/Ombitasvir + Dasabuvir in Patients with Chronic Kidney Diseases: Results from ERCHIVES
44. HCV Treatment Initiation in Patients with Chronic Kidney Disease: Results from ERCHIVES
45. A Comparison of Daily Average Consumption (DACON) of Oxycodone and Oxymorphone Long-Acting Oral Tablets
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.